文献速递淋巴瘤

SOCS1突变对弥漫性大B细胞淋巴瘤的影响

The impact of SOCS1 mutations in diffuse large B-cell lymphoma.
PubMed 文献 · Br J Haematol · 2019-08-12

SOCS1突变在原发纵隔B细胞淋巴瘤和经典霍奇金淋巴瘤中频繁发生,在后者中影响蛋白长度并与生存期缩短相关。两项独立研究对SOCS1突变在弥漫性大B细胞淋巴瘤(DLBCL)中的预后影响结果不一,可能因样本量小、人口学异质性和治疗方案不同所致。本研究在RICOVER-60队列中评估SOCS1突变,该队列为61-80岁老年患者,统一接受CHOP-14方案联合或不联合利妥昔单抗治疗。携带推定致病性SOCS1突变的患者在CHOP联合利妥昔单抗组中总生存期显著降低,提示这些突变可能削弱CD20抗体治疗的获益。

要点

  • 在CHOP联合利妥昔单抗治疗的老年DLBCL患者中,推定致病性SOCS1突变与总生存期显著降低相关。
  • 推定致病性SOCS1突变可能削弱利妥昔单抗的治疗获益。
  • 既往全外显子组和转录组测序数据提示,预测有害的SOCS1突变在早发性DLBCL中预示生存优势。

核心结论

  • 携带推定致病性SOCS1突变的老年DLBCL患者在CHOP联合利妥昔单抗治疗组中总生存期显著降低,提示这些突变可能削弱CD20抗体治疗的获益。

研究设计与样本

  • 在RICOVER-60队列中评估SOCS1突变,该队列统一为61-80岁老年患者,接受CHOP-14方案联合或不联合利妥昔单抗治疗。
  • 分析患者结局与总体SOCS1突变频率、主要和次要突变及一种新的基于影响的分类器的关系,并与治疗方式进行比较。
  • 比较已发表的大型DLBCL队列全外显子组和转录组测序数据。

主要发现

  • 携带推定致病性SOCS1突变的患者在CHOP联合利妥昔单抗组中总生存期显著降低。
  • 推定致病性SOCS1突变似乎削弱了治疗性CD20抗体的有益效应。
  • 已发表的全外显子组和转录组测序数据证实,预测有害的SOCS1突变在早发性DLBCL中预示突出的生存优势。

局限性

  • 既往两项独立研究结果不一,可能因纳入患者数量少、人口学特征异质性和治疗方案不同所致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mutations in SOCS1 are frequent in primary mediastinal B-cell lymphoma and classical Hodgkin lymphoma. In the latter, SOCS1 mutations affect the length of the encoded protein (major mutations) and are associated with shorter patient survival. Two independent studies examined the prognostic impact of SOCS1 mutations in diffuse large B-cell lymphoma (DLBCL) and showed differing results. This may be due to the small number of included patients, the heterogeneity of patients' demographics and the distinct treatment schemes in these studies. To overcome the size limitations of these previous studies, we assessed SOCS1 mutations in the RICOVER-60 cohort. The cohort uniformly consists of elderly patients (aged 61-80 years) treated with the CHOP-14 scheme (cyclophosphamide, hydroxydaunorubicin, vincristine, prednisolone at 14-day intervals) with or without an additional rituximab treatment. Patient outcomes were analysed with regard to overall SOCS1 mutation frequency, major and minor mutations and a novel impact-based classifier - against the treatment modalities. Patients harbouring putative pathogenic SOCS1 mutations showed significant reduced overall survival within the CHOP plus rituximab group. Hence, putative pathogenic SOCS1 mutations seem to efface the beneficial effect of the therapeutic CD20 antibody. Comparing published data of whole exome and transcriptome sequencing of a large DLBCL cohort confirmed that predicted deleterious SOCS1 mutations forecast pre-eminent survival in early onset DLBCL.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Mellert K, Martin M, Lennerz JK, et al. The impact of SOCS1 mutations in diffuse large B-cell lymphoma. Br J Haematol. 2019. PMID: 31407320. doi:10.1111/bjh.16147

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。